Literature DB >> 27795306

Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Eleanor M Wilson1,2, Elana S Rosenthal2, Sarah Kattakuzhy1,2, Lydia Tang1, Shyam Kottilil3,4.   

Abstract

Directly acting antiviral (DAA) combination therapies for chronic hepatitis C virus (HCV) infection are highly effective, but treatment decisions remain complex. Laboratory testing is important to evaluate a range of viral, host, and pharmacological factors when considering HCV treatment, and patients must be monitored during and after therapy for safety and to assess the viral response. In this review, we discuss the laboratory tests relevant for the treatment of HCV infection in the era of DAA therapy, grouped according to viral and host factors.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  directly acting antiviral therapy; hepatitis C virus; viral resistance

Mesh：

Substances：

Year:  2016        PMID： 27795306      PMCID： PMC5217793          DOI： 10.1128/CMR.00037-16

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN： 0893-8512            Impact factor:   26.132


  116 in total

1.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

2.  Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.

Authors:  Anne De Monte; Johan Courjon; Rodolphe Anty; Eric Cua; Alissa Naqvi; Véronique Mondain; Jacqueline Cottalorda; Laurence Ollier; Valérie Giordanengo
Journal:  J Clin Virol       Date:  2016-03-03       Impact factor: 3.168

3.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Authors:  Thomas B Kelleher; Shruti H Mehta; Ramakrishnan Bhaskar; Mark Sulkowski; Jacquie Astemborski; David L Thomas; Richard E Moore; Nezam H Afdhal
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

4.  Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.

Authors:  Jérôme Boursier; Victor de Ledinghen; Jean-Pierre Zarski; Isabelle Fouchard-Hubert; Yves Gallois; Frédéric Oberti; Paul Calès
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

Review 5.  The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.

Authors:  Cherrishe Bickerstaff
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-08-09       Impact factor: 2.217

6.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

7.  Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.

Authors:  Eric J Lawitz; Hadas Dvory-Sobol; Brian P Doehle; Angela S Worth; John McNally; Diana M Brainard; John O Link; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 8.  The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management.

Authors:  Dimitris Konstantinou; Melanie Deutsch
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

9.  Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

Authors:  David A DeGoey; John T Randolph; Dachun Liu; John Pratt; Charles Hutchins; Pamela Donner; A Chris Krueger; Mark Matulenko; Sachin Patel; Christopher E Motter; Lissa Nelson; Ryan Keddy; Michael Tufano; Daniel D Caspi; Preethi Krishnan; Neeta Mistry; Gennadiy Koev; Thomas J Reisch; Rubina Mondal; Tami Pilot-Matias; Yi Gao; David W A Beno; Clarence J Maring; Akhter Molla; Emily Dumas; Andrew Campbell; Laura Williams; Christine Collins; Rolf Wagner; Warren M Kati
Journal:  J Med Chem       Date:  2014-01-15       Impact factor: 7.446

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
View more
  2 in total

Review 1.  Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.

Authors:  Rebecca Lee; Shyam Kottilil; Eleanor Wilson
Journal:  Hepatol Int       Date:  2016-12-07       Impact factor: 9.029

2.  HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul.

Authors:  Mehmet Emin Bulut; Ummuhan Su Topalca; Ali Murat; Leyla Teke; Hazan Zengin Canalp; Murat Ocal; Banu Bayraktar
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.